Progress in Clinical Neurosciences: Sepsis-Associated Encephalopathy: Evolving Concepts

John X. Wilson and G. Bryan Young

Abstract: Systemic sepsis commonly produces brain dysfunction, sepsis-associated encephalopathy, which can vary from a transient, reversible encephalopathy to irreversible brain damage. The encephalopathy in the acute phase clinically resembles many metabolic encephalopathies: a diffuse disturbance in cerebral function with sparing of the brain stem. The severity of the encephalopathy, as reflected in progressive EEG abnormalities, often precedes then parallels dysfunction in other organs. Recent research has revealed a number of potentially important, non-mutually exclusive, mechanisms that have therapeutic implications.


Sepsis is the systemic response to microorganisms or their toxins.1 There is abundant evidence that this response is produced by inflammatory mediators or cytokines.1 Confusion regarding the role of infection has arisen because trauma, burns and pancreatitis may produce the same systemic response with release of inflammatory mediators, in the absence of infection. Thus, the systemic inflammatory response syndrome may or may not have an underlying infectious agent and consists of fever or hypothermia, tachycardia, tachypnea, hyperdynamic circulation, hypercatabolic state and evidence of organ hypoperfusion or organ dysfunction.1

Brain dysfunction or encephalopathy is a common accompaniment to systemic inflammatory response syndrome. We have used the term sepsis-associated encephalopathy (SAE)2 to define a diffuse or multifocal cerebral dysfunction as a component of infection (i.e., there should be an identified microorganism) with systemic response but without clinical or laboratory evidence of direct brain infection (i.e., we exclude meningitis or macroscopic cerebritis or brain abscesses). We suggest that SAE is preferable to the loosely used term “septic encephalopathy” which to some implies a consistent, direct infection of the central nervous system.

Sepsis-associated encephalopathy is a common problem with serious consequence. In our studies of hospital patients with bacteremia, 87% had abnormal electroencephalograms (EEG) and 70% were diagnosed with neurologic symptoms ranging from lethargy to coma.2-4 Forty-six percent of these patients with brain dysfunction were in the intensive care unit, with the rest on the wards. Survivors of severe sepsis were often left with debilitating cognitive and behavioral problems that persisted for years or were irreversible.5

Pathology and Pathophysiology

In fatal cases, watershed brain infarctions from sustained hypotension are rarely encountered, however the brain may show microscopic abnormalities.6 Eight of 12 of our patients with postmortem examinations had disseminated microabscesses. The cerebral cortex is the site most commonly involved, but deep structures and even the spinal cord may be affected. Other less common lesions include multiple microscopic infarctions, brain purpura and central pontine myelinolysis.6 Some cases may show no abnormality on gross or light microscopic examination.

From the Departments of Physiology (JXW) and Clinical Neurological Sciences (GBY), the University of Western Ontario, London, Ontario, Canada.

Received April 22, Accepted in final form September 4, 2002.

Reprint requests to: G.B. Young, Division of Neurology, Sunnybrook and Women’s Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5


The Canadian Journal of Neurological Sciences

Downloaded from https://www.cambridge.org/core, IP address: 54.70.40.11, on 02 Mar 2019 at 16:52:42, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S031716710005335X
The mechanisms of SAE are uncertain. In advanced cases it is likely multifactorial, given the variety of pathological findings. The early, fully reversible cases are not likely associated with structural change and are probably metabolic in nature. Other mechanisms, in addition to the metabolic disturbances, operate in more advanced cases. The following mechanisms have been proposed:

1. Microvascular disorder

Reduced cerebral blood flow and increased cerebrovascular resistance are found in human cases of SAE. Microthromboses and microinfarctions may also occur. At least some of these phenomena likely relate to the production of cytokines [e.g., tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ)] and interleukins (IL) and their effects on the production of nitric oxide (NO) by endothelial nitric oxide synthase (eNOS). Inhibition of eNOS leads to impairment of the microcirculation of the brain and other organs by causing vasconstriction. In addition, sepsis is a procoagulant state that rests with endothelial dysfunction: endothelial cells convert protein C to activated protein C that has anti-inflammatory and profibrinolytic properties. Indeed, organ dysfunction in sepsis can be improved by the administration of activated protein C. The brain may be similar to other organs in this respect. The blood-brain barrier, which normally maintains a homeostatic environment for brain cells, becomes leaky in a dynamic and patchy manner within the first few hours of endotoxemia in experimental animals. In addition, the differential flux of chemicals across the blood-brain barrier is altered in sepsis; e.g., aromatic chain amino acids are more readily transported than branched chain amino acids from blood to brain. Inflammatory cytokines and free radicals likely produce these effects on capillary permeability.

2. Amino acids and neurotransmitter imbalance

Septic humans and animal models of sepsis both show an increased ratio of aromatic to branched-chain amino acids in the plasma. This altered ratio correlates with decreased norepinephrine, dopamine and serotonin concentrations in the brains of septic rats. There are a number of factors that are yet to be explored, such as the concentration of gamma-aminobutyric acid (GABA), the activity of GABA receptors in the brain, and the levels of benzodiazepine-like substances (with inhibitory or sedating properties) and quinolinic acid that are elevated in hepatic dysfunction.

3. Brain microabscesses

These are of uncertain significance with respect to the pathogenesis of encephalopathy. Because they are microscopic, they are not detected in life, even with high-resolution MRI scans. There is an association of brain microabscesses with retinal microabscesses, which are a rarity in our experience. There is no good way of knowing when microabscesses occur in the course of sepsis but, based on the surrounding reaction in the brain, probably they are not all agonal. Indeed, a recent paper found microabscesses to be one of the pathological conditions associated with central autonomic dysfunction in sepsis. Microabscesses could cause further neuronal damage and dysfunction due to local release of cytokines and other inflammatory mediators.

4. Failure of other organs

Hepatic or renal failure may, in themselves, cause an encephalopathy. Since SAE often precedes multi-organ failure, this secondary mechanism would not explain the early encephalopathy of sepsis. However, multi-organ failure likely plays a contributory role in producing brain dysfunction in advanced sepsis.

5. Cytokine actions in the brain

Pro-inflammatory cytokines released by activated neutrophils and monocytes include interleukin-1 (IL-1α and IL-1β), IL-6 and TNF-α. Interleukin-1 can stimulate vagal afferents that, in turn, affect brainstem, limbic and hypothalamic structures to produce “illness behavior” characterized by decreased activity, anorexia, depressed mood and cognitive impairment. Interleukin-1 stimulates the production of prostaglandin E-2 by brain endothelial cells. This produces fever and activation of the hypothalamic-pituitary adrenal axis to increase cortisoid production. Interleukin-1β may directly affect a number of brain nuclei in circumventricular organs that are not guarded by the blood-brain barrier (including the area postrema) and choroid plexus. Activation of these structures could alter limbic function in the amygdala and hypothalamus, thereby causing depression and anorexia. Administration of TNF-α alters the brain’s metabolism of tryptophan to produce more kynuramine (that is converted to the neurotoxin quinolinic acid) and less serotonin; these biochemical changes are associated with emotional depression.

A recent study revealed that peripheral inflammation leads to the activation of “signal transducer and activator of transcription 3” (STAT3), first in brain cells near the blood-brain barrier and brain-CSF interfaces and then throughout much of the brain parenchyma, possibly through the mediation of pro-inflammatory cytokines. As the activated cells proved to be astrocytes, this study adds support to the concept that SAE relates to an altered interaction of astrocytes and neurons (see below).

6. Excitotoxicity and oxidative stress

Antibiotics often fail to prevent neurologic complications of sepsis, in part because antibiotic destruction of bacteria releases endotoxins [e.g., Escherichia coli lipopolysaccharide (LPS)] that stimulate inflammation. Lipopolysaccharide increases cerebral levels of pro-inflammatory cytokines such as interferon γ (IFN-γ). Together, LPS and cytokines induce the reactive phenotype in brain astrocytes and upregulate inducible nitric oxide synthase (iNOS) in these and other cell types. Nitric oxide synthase enzymes use reduced nicotinamide adenine dinucleotide phosphate (NADPH), oxygen and arginine to produce NO and superoxide. These products kill invading organisms but also evoke oxidative stress in host cells.

Septic processes can be studied in primary astrocyte cultures, where the combination of LPS and IFN-γ (i.e., LPS + IFN-γ) induces expression of iNOS. Lipopolysaccharide + IFN-γ also upregulates the argininosuccinate synthetase that produces the NOS substrate L-arginine and thus enhances NO production in astrocytes. These changes indicate that glial argininosuccinate synthetase and iNOS contribute to the increased cerebral NO levels caused by LPS + IFN-γ in situ. The high NO levels inhibit

LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES

Volume 30, No. 2 – May 2003
Downloaded from https://www.cambridge.org/core, IP address: 54.70.40.11, on 02 Mar 2019 at 16:52:42, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S031716710005335X
mitochondrial respiration, at least in part by decreasing the affinity of cytochrome c oxidase for oxygen.\textsuperscript{44} Additionally, NO combines with superoxide to form peroxynitrite, which inhibits respiratory and glycolytic enzymes, leading to energy depletion in brain cells.\textsuperscript{35} Indeed, adenosine triphosphate (ATP) content drastically decreases in glial cultures exposed to LPS + IFN\textsubscript{γ}.\textsuperscript{36} The mitochondrial dysfunction depletion may explain why sepsis-induced elevation of NO production is accompanied by increases in extracellular hydrogen peroxide.\textsuperscript{37} Lipopolysaccharide + IFN\textsubscript{γ} also increases intracellular oxidants and depletes glutathione from astrocytes.\textsuperscript{38} In mixed neuron-astrocyte cultures, LPS+IFN\textsubscript{γ} induces iNOS expression in the astrocytes and sensitizes the neurons to killing by oxygen-glucose deprivation.\textsuperscript{39}

Sepsis-associated encephalopathy also involves excitotoxicity by glutamate. Septicemia elevates glutamate concentration 5-fold in the brain interstitial fluid.\textsuperscript{40} Similarly, injection of LPS\textsuperscript{41} or NO donors\textsuperscript{42} increases extracellular glutamate concentration in brain. The extracellular glutamate activates N-methyl D-aspartate (NMDA)-type glutamatergic receptors to extents that stimulate or injure susceptible neurons. For example, LPS elicits cardiovascular responses that can be prevented by blockade of NMDA-type glutamatergic receptors in brain.\textsuperscript{43} Furthermore, administration of an NMDA antagonist lessens the destruction of cholinergic neurons caused by LPS.\textsuperscript{44} High extracellular glutamate levels probably account for the increased incidence of seizure in critically ill patients.\textsuperscript{45} An increased concentration of extracellular glutamate also initiates a gradual down-regulation of the expression and activity of NMDA receptors.\textsuperscript{46} This impairs the responsiveness of surviving neurons to glutamate and may contribute to patients becoming obtunded.

The rise in extracellular glutamate following a septic insult may be due, at least partially, to inhibition of astrocytic clearance of this transmitter. Septic induction of iNOS is associated with inhibition of glutamate clearance in mixed neuron-astrocyte cultures, where LPS + IFN\textsubscript{γ} potentiates the rise in extracellular glutamate concentration caused by oxygen-glucose deprivation.\textsuperscript{39} Under normal conditions, glutamate is removed from synaptic spaces by high-affinity, Na\textsuperscript{+}-dependent transporters (EAAT) located on astrocytes. Inhibition of the EAAT transporters has been shown to trigger neurologic dysfunction under nonseptic conditions.\textsuperscript{47} We observed that LPS + IFN\textsubscript{γ} slows Na\textsuperscript{+}-dependent glutamate uptake by astrocytes.\textsuperscript{31} When septic insults induce iNOS, the abundant peroxynitrite that is produced inhibits EAAT directly.\textsuperscript{48,49} Furthermore, the oxidants produced in immune-stimulated astrocytes inhibit ATP synthesis.\textsuperscript{50} The subsequent fall in intracellular ATP concentration, by inhibiting Na\textsuperscript{+}K\textsuperscript{+}-ATPase, may collapse the Na\textsuperscript{+} gradient across the plasma membrane and thereby decrease the force driving glutamate uptake. Oxidative stress in astrocytes also leads to cell swelling and opening of channels or pores in the plasma membrane, through which glutamate exits.\textsuperscript{51,52} Thus, oxidants accelerate glutamate efflux from the cytoplasm of astrocytes, where glutamate concentration normally is 1000-fold higher than in extracellular fluid.\textsuperscript{52}

Endogenous antioxidants like ascorbate (vitamin C) prevent the injurious effects of oxidants. Ascorbate is present at millimolar concentrations in brain cells, where it reduces reactive oxygen and nitrogen species.\textsuperscript{53} As it donates electrons to oxidants, ascorbate becomes oxidized to ascorbyl radical and then to dehydroascorbic acid. Subsequently, reducing equivalents derived from cell metabolism (e.g., NADPH generated by the pentose phosphate pathway of glucose metabolism) reduce the dehydroascorbic acid and ascorbyl radical to ascorbate. In sepsis, however, ascorbate may be oxidized by reactive oxygen species at rates that overwhelm the ability of cells to regenerate the vitamin. The observation that the concentration of ascorbic radical is increased in septic patients\textsuperscript{54} is consistent with an imbalance in the redox cycling of ascorbate. Because brain cells cannot synthesize ascorbate de novo from glucose, they rely on blood and cerebrospinal fluid. This extracellular supply is diminished in sepsis because ascorbate concentrations in blood, peripheral tissues and cerebrospinal fluid fall below normal.\textsuperscript{55-61} Additionally, cellular mechanisms of ascorbate transport and redox cycling may be defective, since LPS depletes ascorbate from lung,\textsuperscript{58} adrenal glands,\textsuperscript{62} and heart.\textsuperscript{63}

Brain cells take up extracellular ascorbate through specific, EAAT.\textsuperscript{64,65} Exposure of astrocytes to LPS + IFN\textsubscript{γ} inhibits the initial rate of Na\textsuperscript{+}-dependent ascorbate uptake.\textsuperscript{31} A faster way that astrocytes normally accumulate ascorbate is by taking up dehydroascorbic acid and reducing it to ascorbate.\textsuperscript{66,67} Some of the ascorbate is released subsequently and may become available to other brain cells. Brief (30-min) exposure to peroxyl radicals or 24 h exposure to LPS + IFN\textsubscript{γ} decrease the rate of accumulation of intracellular ascorbate from extracellular dehydroascorbic acid.\textsuperscript{31,66} After dehydroascorbic acid is taken into cells it is reduced to ascorbate by cytosolic dehydroascorbic acid reductase or other enzymes, using reducing equivalents from NADPH or glutathione.\textsuperscript{67-69} It is this process of dehydroascorbic acid reduction that may be affected by septic insults. Nitric oxide synthase activity can influence dehydroascorbic acid concentration by consuming NADPH and by producing oxidants. Because NADPH is used for the reduction of glutathione disulfide to glutathione, the synthesis of NO by NOS, and the enzymatic reduction of dehydroascorbic acid to ascorbate, a scarcity of NADPH may limit dehydroascorbic acid reduction in septic cells. Furthermore, NOS activity increases the production of oxidants (e.g., peroxynitrite) that can strip electrons from ascorbate and thereby regenerate dehydroascorbic acid intracellularly. Administering a blocker of NOS activity lessens the effect of LPS + IFN\textsubscript{γ} on dehydroascorbic acid reduction to ascorbate in astrocytes.\textsuperscript{31} Therefore, excessive production of reactive nitrogen species (e.g., peroxynitrite) during the inflammatory response to LPS + IFN\textsubscript{γ} appears to mediate the inhibition of ascorbate accumulation observed in septic glia. Intracellular dehydroascorbic acid that is not reduced to ascorbate exits cells and thus septic astrocytes fail to clear dehydroascorbic acid from extracellular fluid. In brain, this inadequate clearance of extracellular dehydroascorbic acid may contribute to encephalopathy because high concentrations of dehydroascorbic acid are directly toxic to neurons.\textsuperscript{70}

7. Apoptosis

Apoptosis is a form of programmed cell death that may be triggered by TNF-α stimulation of neuronal receptors that activate caspase enzymes. An alternative mechanism involves mitochondrial damage that triggers apoptosis. A recent study
8. Treatment-related causes

We should not forget iatrogenically-induced encephalopathy. Drugs often show delayed clearance in sepsis. Sedative drugs, especially benzodiazepines and narcotics, may accumulate when used for several days, especially if clearance is impaired due to organ failure and endotoxin-mediated inhibition of the cytochrome P450 system. Some medications, e.g., penicillin in patients with renal failure, imipenem and aminophylline, may produce seizures that could be convulsive or nonconvulsive. Various fluid, electrolyte (including calcium, magnesium and phosphate) and osmotic disorders may accompany disorders of water homeostasis, enteral or parenteral feeding, renal impairment and errors in fluid replacement. Some volume expanders may produce hemorrhagic complications and hypocalcemia. Encephalopathies related to cardiopulmonary by-pass procedures and organ transplantations are well-documented.

CLINICAL FEATURES

Sepsis-associated encephalopathy is a diffuse disturbance in cerebral function. The principal neurological findings relate to altered mental status. Mildly encephalopathic patients demonstrate a fluctuating confusional state and inappropriate behavior. Inattention and writing errors (including spelling, writing full sentences, orientation of writing on the page) are common. More severely affected patients show delirium, an agitated confusional state or coma.

The most common motor sign is paratonic rigidity or gegenhalten, a resistance to passive movement of limbs that is velocity-dependent: the resistance felt during movements at normal rate disappears when the limb is moved slowly. Asterixis, multifocal myoclonus, seizures and tremor are relatively infrequent. Cranial nerve functions are almost invariably spared. Lateralized features, such as gaze palsy or a hemiparesis are almost never encountered; such findings should prompt investigation for other etiologies, especially ones with macroscopic focal lesions.

Clinical or laboratory evidence of peripheral nerve dysfunction, namely critical illness polyneuropathy, is found in 70% of our encephalopathic patients. The neuropathy is axonal in type and takes many months to resolve. It is later in onset and much slower to recover than the encephalopathy. Clinically, one finds decreased movement and the loss of deep tendon reflexes. Motor function is usually more affected than sensation, so that the patient may grimace without other movement when a nail bed is squeezed. In severe cases, the polyneuropathy may affect the phrenic nerves, creating problems in weaning the patient from the ventilator.

Patients with SAE hyperventilate (low PaCO₂), initially related to a respiratory alkalosis and often in later stages due to a metabolic acidosis. The latter likely relates to poor tissue perfusion with increased lactate or to renal impairment as a complication of sepsis.

The relative time course of the encephalopathy, the failure to wean from the ventilator (often due to critical illness polyneuropathy or myopathy) and the resolution of critical illness polyneuropathy is illustrated in Figure 1.

LABORATORY INVESTIGATIONS

The electroencephalogram (EEG) serves as the most sensitive test for SAE. It may show mild, diffuse, reversible slowing in bacteremia, even if the neurological examination is normal. The severity of the EEG abnormality is parallel to the mental status impairment. As the encephalopathy worsens, mild slowing in the theta (4 to 8Hz) range is followed by diffuse delta (4Hz) waves, then generalized triphasic waves and finally by suppression or a generalized burst-suppression (alternating diffuse reductions in voltage with burst of higher voltage waves) pattern. The relationships of EEG classifications to severity of encephalopathy and mortality are illustrated in Figures 2 and 3.

In bacteremic patients, mortality is directly related to the severity of the EEG abnormality: 0% with normal, 19% with theta, 36 with delta, 50% with triphasic waves and 67% with suppression or burst-suppression.

Computed tomographic brain scans are normal. In our experience MRI scans are usually unremarkable, but occasional patients show various degrees of vasogenic edema (unpublished observations). This fits with the neuropathology and experimental studies (see above): neuronal loss and microabscesses are microscopic, but the blood-brain barrier can be disrupted in a dynamic, multifocal fashion. Cerebrospinal fluid analysis shows only a mild elevation of protein.
concentration in some, but not all, of the patients and normal cell counts and glucose concentrations, even in patients with brain microabscesses at autopsy.1

We find no significant correlation of severity of encephalopathy with any specific bacteria but there is a trend for patients with multiple bacteria on blood culture and with Candida albicans to have more severe brain dysfunction and a higher mortality rate.1

The following biochemical tests show a direct proportional change with the severity of the encephalopathy: serum urea, creatinine, bilirubin and alkaline phosphatase. The degree of renal impairment is rarely sufficient to account for the brain dysfunction.1 Hepatic failure is, however, usually difficult to assess clinically or to quantify biochemically. Encephalopathic septic patients have greater elevation of aromatic amino acids and lower concentrations of branched chain amino acids in plasma than do nonencephalopathic patients.15 This is similar to the unbalanced ratio found in hepatic failure. In sepsis, however, it may relate mainly to altered metabolism of amino acids in muscle and liver.

**MANAGEMENT**

First one must establish the diagnosis. Sepsis-associated encephalopathy is a diagnosis of exclusion: there should be no clinical or laboratory evidence of direct central nervous system infection (e.g., meningitis, macroscopic intracranial abscess or empyema), head trauma, fat embolism, adverse reactions to medications, or sedative or paralyzing drug effects. It is especially important to perform a lumbar puncture on obtunded patients with systemic inflammatory response syndrome, to rule out meningitis.

Seizures (uncommon) should be treated with standard anti-epileptic medications such as phenytoin.

Patients usually die due to the severity of the systemic illness or of failure of organs other than the brain.1 Clinicians and nurses should be watchful for early encephalopathy, as it can be a presenting feature of sepsis. Prompt, specific treatment of the septic illness (appropriate antimicrobial therapy, drainage of abscesses, etc.) with prevention of multi-organ failure will save lives, as mortality is directly related to the severity of sepsis and the number of failed organs.82 With the administration of a
mixture of amino acids with high concentrations of branched-chain amino acids, Freund and colleagues successfully reversed SAE in five patients. This short-term improvement is gratifying, but such treatment may not be helpful for advanced cases with multi-organ failure.

Antibiotics may fail for several reasons. First, the bacteria may be resistant. Second, the antibiotics may act too slowly, leaving sufficient time for severe inflammatory injury to develop. Third, the killing of bacteria may release inflammatory agents such as LPS.

Drugs or agents, e.g., activated protein C, that affect or counteract the procoagulant state in sepsis may be directly or indirectly beneficial to brain function in sepsis. However, the potential benefits of this therapy on SAE directly will be difficult to separate from systemic effects.

Future therapies may combine antibiotics with drugs that slow the production of reactive nitrogen and oxygen species triggered by septic insults. For example, ascorbate is a hydrophilic antioxidant that improves survival and decreases morbidity in animals after LPS administration or peritonitis. Ascorbate also prevents LPS-induced free radical production, protein oxidation, lipid peroxidation and apoptosis in peripheral tissues. In vitro experiments have shown that adding ascorbate or ascorbate-phosphate to primary astrocyte cultures increases intracellular ascorbate concentration and attenuates iNOS induction by LPS + IFNγ. Furthermore, intracellular ascorbate decreases inhibition of astrocytic glutamate uptake by LPS + IFNγ. Millimolar concentrations of ascorbate reduce superoxide and thereby prevent peroxynitrite formation from superoxide and NO. This effect is physiologically relevant because the steady-state intracellular ascorbate concentration can reach approximately 10 mM in some cell types (e.g., astrocytes). Ascorbate also chemically reduces peroxynitrite and other reactive oxygen and nitrogen species. These scavenging actions may explain how ascorbate diminishes the levels of oxidizing free radicals in LPS-exposed myocardium and neutrophils and lessens LPS-induced oxidative modification of proteins in liver. Both ascorbate and antioxidant enzymes (superoxide dismutase and catalase) are capable of decreasing the induction by inflammatory cytokines of NOS activity in vascular endothelial cell cultures. Pretreatment of astrocytes with ascorbate-phosphate, to elevate the intracellular concentration of ascorbate prior to LPS + IFNγ exposure, or co-administration of an inhibitor of NOS activity, protects glutamate uptake rate. Taken together, these observations indicate that antioxidant effects of ascorbate may prevent iNOS induction and contribute to the preservation of normal cell function during exposure to bacterial toxins. Treatments that increase intracellular ascorbate concentration may be beneficial for patients at risk for neurologic complication in sepsis. By preserving the glutamate clearance function of astrocytes, intracellular ascorbate may allow these cells to regulate the composition of the extracellular fluid and thereby protect neurons. Systemic administration of ascorbic acid (20 mg/kg) has been shown in rats to increase the concentration of ascorbate and decrease the level of reactive oxygen species in the extracellular fluid of the striatum. Because intravenous injection of ascorbic acid may aggravate systemic acidosis in patients, it may be preferable to administer the sodium salt of ascorbate.

Estrogens are lipophilic antioxidants that may contribute to gender differences in sepsis, which include a significantly better prognosis for women. Astrocytes are essential mediators of the neuroprotective actions of estrogens after ischemia and may have a similar role in sepsis since, for example, 17β-estradiol attenuates LPS-induced NF-κB nuclear translocation in rat astrocytes. The concentration of 17β-estradiol (1 μM) may have been high enough to effectively scavenge free radicals and thereby inhibit oxidative modification of NF-κB subunits or other proteins involved in cell signalling. The conjugate phenoxy radical of 17β-estradiol is unusually reactive toward ascorbate by H-atom transfer. Thus estradiol and ascorbate may function together synergistically as antioxidants.

**Conclusion**

Sepsis-associated encephalopathy is a syndrome consisting of a diffuse disturbance in cerebral function that occurs in the context of infection in the body but without clinical or laboratory evidence of CNS infection. The mortality is highest in those with more severe cerebral dysfunction, as reflected in EEG grade. The neurological outcome is dichotomous: mild cases likely recover completely, while survivors of severe sepsis may have deficits. This reflects the varied pathology and pathogenesis of SAE. Mild cases are similar to other metabolic encephalopathies and involve reversible metabolic, neurotransmitter or microcirculatory disorders. Iatrogenic factors, often related to impaired drug clearance, play a contributory role. In severe cases, the neurons and glia may be lost due to irreversible ischemic, excitotoxic or oxidative stress or activation of apoptotic mechanisms. Although the pathogenesis remains hypothetical, recent research raises the possibility of therapeutic intervention. Eradication of the underlying infection remains the cornerstone of treatment, as this corrects the systemic inflammatory response and allows organs, including the brain, to recover. Specific strategies to spare neuronal and glial death should be considered. Those that appear promising are ones that will not compromise the general immunological defenses, but will offset oxidative stresses, focal ischemia and apoptosis in the brain. This should be testable in animal or tissue culture models and in clinical trials in humans.

**References**


